Prevalence, Risk Factors And Treatment Of The Most Common Gram-Negative Bacterial Infections In Liver Transplant Recipients: A Review

References

• Black CK, Termanini KM, Aguirre O, Hawksworth JS, Sosin M. Solid organ transplantation in the 21(st) century. Ann Transl Med. 2018;6(20):409. doi:10.21037/atm.2018.09.6830498736
   PubMed Web of Science ®Google Scholar
• Wadström J, Ericzon B-G, Halloran PF, et al. Advancing transplantation: new questions, new possibilities in kidney and liver transplantation. Transplantation. 2017;101(2):S1–S42. doi:10.1097/TP.0000000000001563
   Web of Science ®Google Scholar
• Lim S, Kim EJ, Lee TB, et al. Predictors of postoperative infectious complications in liver transplant recipients: experience of 185 consecutive cases. Korean J Intern Med. 2018;33(4):798–806. doi:10.3904/kjim.2017.23029466849
   PubMed Web of Science ®Google Scholar
• Righi E. Management of bacterial and fungal infections in end stage liver disease and liver transplantation: current options and future directions. World J Gastroenterol. 2018;24(38):4311–4329. doi:10.3748/wjg.v24.i38.431130344417
   PubMed Web of Science ®Google Scholar
• Li C, Wen T-F, Mi K, Wang C, Yan L-N, Li B. Analysis of infections in the first 3-month after living donor liver transplantation. World J Gastroenterol. 2012;18(16):1975. doi:10.3748/wjg.v18.i16.197522563180
   PubMed Web of Science ®Google Scholar
• Kim YJ, Yoon JH, Kim SI, et al. High mortality associated with Acinetobacter species infection in liver transplant patients. Transplant Proc. 2011;43(6):2397–2399. doi:10.1016/j.transproceed.2011.06.01121839276
   PubMed Web of Science ®Google Scholar
• Gagliotti C, Morsillo F, Moro ML, et al. Infections in liver and lung transplant recipients: a national prospective cohort. Eur J Clin Microbiol Infect Dis. 2018;37(3):399–407. doi:10.1007/s10096-018-3183-029380226
   PubMed Web of Science ®Google Scholar
• Qiao B, Wu J, Wan Q, Zhang S, Ye Q. Factors influencing mortality in abdominal solid organ transplant recipients with multidrug-resistant gram-negative bacteremia. BMC Infect Dis. 2017;17(1):171. doi:10.1186/s12879-017-2276-128241746
   PubMed Web of Science ®Google Scholar
• Cervera C, van Delden C, Gavalda J, Welte T, Akova M, Carratala J. Multidrug-resistant bacteria in solid organ transplant recipients. Clin Microbiol Infect. 2014;20 Suppl 7:49–73. doi:10.1111/1469-0691.12687
   Web of Science ®Google Scholar
• Ferrarese A, Zanetto A, Becchetti C, et al. Management of bacterial infection in the liver transplant candidate. World J Hepatol. 2018;10(2):222–230. doi:10.4254/wjh.v10.i2.22229527258
   PubMed Web of Science ®Google Scholar
• Song SH, Li XX, Wan QQ, Ye QF. Risk factors for mortality in liver transplant recipients with ESKAPE infection. Transplant Proc. 2014;46(10):3560–3563. doi:10.1016/j.transproceed.2014.08.04925498089
   PubMed Web of Science ®Google Scholar
• Linares L, Cervera C, Hoyo I, et al. Klebsiella pneumoniae infection in solid organ transplant recipients: epidemiology and antibiotic resistance. Transplant Proc. 2010;42(8):2941–2943. doi:10.1016/j.transproceed.2010.07.08020970577
   PubMed Web of Science ®Google Scholar
• Kim HK, Park YK, Wang HJ, et al. Epidemiology and clinical features of post-transplant bloodstream infection: an analysis of 222 consecutive liver transplant recipients. Infect Chemother. 2013;45(3):315–324. doi:10.3947/ic.2013.45.3.31524396633
   PubMedGoogle Scholar
• Lübbert C, Rodloff AC, Laudi S, et al. Lessons learned from excess mortality associated with Klebsiella pneumoniae carbapenemase 2–producing K. pneumoniae in liver transplant recipients. Liver Transplant. 2014;20(6):736–738. doi:10.1002/lt.v20.6
   Web of Science ®Google Scholar
• Aguado JM, Silva JT, Fernandez-Ruiz M, et al. Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev (Orlando). 2018;32(1):36–57. doi:10.1016/j.trre.2017.07.00128811074
   PubMedGoogle Scholar
• Mouloudi E, Massa E, Piperidou M, et al. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study. Transplant Proc. 2014;46(9):3219–3221. doi:10.1016/j.transproceed.2014.09.16025420864
   PubMed Web of Science ®Google Scholar
• Pereira MR, Scully BF, Pouch SM, et al. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transplant. 2015;21(12):1511–1519. doi:10.1002/lt.24207
   PubMed Web of Science ®Google Scholar
• Kalpoe JS, Sonnenberg E, Factor SH, et al. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transplant. 2012;18(4):468–474. doi:10.1002/lt.23374
   PubMed Web of Science ®Google Scholar
• Lubbert C, Becker-Rux D, Rodloff AC, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection. 2014;42(2):309–316. doi:10.1007/s15010-013-0547-324217959
   PubMed Web of Science ®Google Scholar
• Giannella M, Bartoletti M, Morelli MC, et al. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization. Am J Transplant. 2015;15(6):1708–1715. doi:10.1111/ajt.1313625754742
   PubMed Web of Science ®Google Scholar
• Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29(12):1099–1106. doi:10.1086/59241218973455
   PubMed Web of Science ®Google Scholar
• Rana MM, Sturdevant M, Patel G, Huprikar S. Klebsiella necrotizing soft tissue infections in liver transplant recipients: a case series. Transpl Infect Dis. 2013;15(4):E157–E163. doi:10.1111/tid.2013.15.issue-423782431
   PubMed Web of Science ®Google Scholar
• Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis. 2012;14(2):198–205. doi:10.1111/j.1399-3062.2011.00688.x22093103
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Giamarellou H, et al. Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2018;24(2):133–144. doi:10.1016/j.cmi.2017.08.03028893689
   PubMed Web of Science ®Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618. doi:10.1093/cid/ciw63627624958
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364. doi:10.1093/cid/ciy49229893802
   PubMed Web of Science ®Google Scholar
• Athans V, Neuner EA, Hassouna H, et al. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient. Antimicrob Agents Chemother. 2019;63(1). doi:10.1128/AAC.00779-19
   Web of Science ®Google Scholar
• Clancy CJ, Chen L, Shields RK, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant. 2013;13(10):2619–2633. doi:10.1111/ajt.1242424011185
   PubMed Web of Science ®Google Scholar
• Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob. 2012;11:32. doi:10.1186/1476-0711-11-3223234297
   PubMed Web of Science ®Google Scholar
• Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect. 2011;17(8):1135–1141. doi:10.1111/j.1469-0691.2011.03553.x21635663
   PubMed Web of Science ®Google Scholar
• van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75(2):115–120. doi:10.1016/j.diagmicrobio.2012.11.00923290507
   PubMed Web of Science ®Google Scholar
• Bai XR, Liu JM, Jiang DC, Yan SY. Efficacy and safety of tigecycline monotherapy versus combination therapy for the treatment of hospital-acquired pneumonia (HAP): a meta-analysis of cohort studies. J Chemother. 2018;30(3):172–178. doi:10.1080/1120009X.2018.142527929405898
   PubMed Web of Science ®Google Scholar
• Cai Y, Bai N, Liu X, Liang B, Wang J, Wang R. Tigecycline: alone or in combination? Infect Dis (Lond). 2016;48(7):491–502. doi:10.3109/23744235.2016.115573526982103
   PubMed Web of Science ®Google Scholar
• Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis. 2012;31(5):695–701. doi:10.1007/s10096-011-1360-521805292
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Hittle LE, O’Hara JA, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60(9):1295–1303. doi:10.1093/cid/civ04825632010
   PubMed Web of Science ®Google Scholar
• Gao F, Ye Q, Wan Q, Liu S, Zhou J. Distribution and resistance of pathogens in liver transplant recipients with Acinetobacter baumannii infection. Ther Clin Risk Manag. 2015;11:501–505. doi:10.2147/TCRM.S8225125848296
   PubMed Web of Science ®Google Scholar
• de Gouvea EF, Martins IS, Halpern M, et al. The influence of carbapenem resistance on mortality in solid organ transplant recipients with Acinetobacter baumannii infection. BMC Infect Dis. 2012;12:351. doi:10.1186/1471-2334-12-35123237530
   PubMed Web of Science ®Google Scholar
• Hsieh CE, Chen YL, Lin PY, et al. Liver transplantation in patients infected with gram-negative bacteria: non-Acinetobacter baumannii and Acinetobacter baumannii. Transplant Proc. 2013;45(1):225–230. doi:10.1016/j.transproceed.2012.09.11423375305
   PubMed Web of Science ®Google Scholar
• Otan E, Aydin C, Usta S, Kutluturk K, Kayaalp C, Yilmaz S. Acinetobacter infection in a liver transplantation intensive care unit. Transplant Proc. 2013;45(3):998–1000. doi:10.1016/j.transproceed.2013.02.07723622607
   PubMed Web of Science ®Google Scholar
• Freire MP, Pierrotti LC, Oshiro IC, et al. Carbapenem-resistant Acinetobacter baumannii acquired before liver transplantation: impact on recipient outcomes. Liver Transplant. 2016;22(5):615–626. doi:10.1002/lt.24389
   Web of Science ®Google Scholar
• Kim YJ, Kim SI, Lee YD, et al. Carbapenem-resistant acinetobacter baumannii bacteremia in liver transplant recipients. Transplant Proc. 2018;50(4):1132–1135. doi:10.1016/j.transproceed.2018.01.04329731080
   PubMed Web of Science ®Google Scholar
• Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med. 2015;36(1):85–98. doi:10.1055/s-0000007525643273
   PubMed Web of Science ®Google Scholar
• Anvarinejad M, Japoni A, Davarpanah MA, Mahmudi H, Mammina C, Vazin A. Phenotypic and molecular epidemiology of acinetobacter calcoaceticus baumannii complex strains spread at Nemazee Hospital of Shiraz, Iran. Jundishapur journal of microbiology. 2015;8(6).
   Web of Science ®Google Scholar
• Reddy P, Zembower TR, Ison MG, Baker TA, Stosor V. Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation. Transplant Infect Dis. 2010;12(1):87–93. doi:10.1111/tid.2010.12.issue-1
   Web of Science ®Google Scholar
• Shields RK, Kwak EJ, Potoski BA, et al. High mortality rates among solid organ transplant recipients infected with extensively drug-resistant Acinetobacter baumannii: using in vitro antibiotic combination testing to identify the combination of a carbapenem and colistin as an effective treatment regimen. Diagn Microbiol Infect Dis. 2011;70(2):246–252. doi:10.1016/j.diagmicrobio.2010.12.02321353436
   PubMed Web of Science ®Google Scholar
• Singh N, Gayowski T, Rihs JD, Wagener MM, Marino IR. Evolving trends in multiple-antibiotic-resistant bacteria in liver transplant recipients: a longitudinal study of antimicrobial susceptibility patterns. Liver Transplant. 2001;7(1):22–26. doi:10.1053/jlts.2001.20769
   PubMed Web of Science ®Google Scholar
• Patel G, Perez F, Bonomo RA. Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii: assessing their impact on organ transplantation. Curr Opin Organ Transplant. 2010;15(6):676–682. doi:10.1097/MOT.0b013e328340437320930636
   PubMed Web of Science ®Google Scholar
• Freire MP, Van Der Heijden IM, do Prado GV, et al. Polymyxin use as a risk factor for colonization or infection with polymyxin-resistant Acinetobacter baumannii after liver transplantation. Transplant Infect Dis. 2014;16(3):369–378. doi:10.1111/tid.2014.16.issue-3
   Web of Science ®Google Scholar
• Korvick JA, Marsh JW, Starzl TE, Yu VL. Pseudomonas aeruginosa bacteremia in patients undergoing liver transplantation: an emerging problem. Surgery. 1991;109(1):62–68.1984637
   PubMed Web of Science ®Google Scholar
• Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs Context. 2018;7:212527. doi:10.7573/1740439829872449
   PubMedGoogle Scholar
• Lee SO, Kang SH, Abdel-Massih RC, Brown RA, Razonable RR. Spectrum of early-onset and late-onset bacteremias after liver transplantation: implications for management. Liver Transplant. 2011;17(6):733–741. doi:10.1002/lt.22296
   PubMed Web of Science ®Google Scholar
• Zhong ZQ, Luo AJ, Wan QQ, Ye QF. Pseudomonas aeruginosa infection among liver transplant recipients: a clinical analysis of 15 cases. Transplant Proc. 2016;48(6):2130–2134. doi:10.1016/j.transproceed.2016.03.05227569958
   PubMed Web of Science ®Google Scholar
• Sun HY, Shields RK, Cacciarelli TV, Muder RR, Singh N. A novel combination regimen for the treatment of refractory bacteremia due to multidrug-resistant Pseudomonas aeruginosa in a liver transplant recipient. Transplant Infect Dis. 2010;12(6):555–560. doi:10.1111/j.1399-3062.2010.00543.x
   PubMed Web of Science ®Google Scholar
• Singh N, Wagener MM, Obman A, Cacciarelli TV, de Vera ME, Gayowski T. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transplant. 2004;10(7):844–849. doi:10.1002/(ISSN)1527-6473
   PubMed Web of Science ®Google Scholar
• Oriol I, Sabe N, Simonetti AF, et al. Changing trends in the aetiology, treatment and outcomes of bloodstream infection occurring in the first year after solid organ transplantation: a single-centre prospective cohort study. Transplant Int. 2017;30(9):903–913. doi:10.1111/tri.2017.30.issue-9
   Web of Science ®Google Scholar
• Liu T, Zhang Y, Wan Q. Pseudomonas aeruginosa bacteremia among liver transplant recipients. Infect Drug Resist. 2018;11:2345–2356. doi:10.2147/IDR.S18028330532566
   PubMed Web of Science ®Google Scholar
• Bodro M, Sabe N, Tubau F, et al. Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients. Transplantation. 2015;99(3):616–622. doi:10.1097/TP.000000000000036625119130
   PubMed Web of Science ®Google Scholar
• Johnson LE, D'Agata EM, Paterson DL, et al. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis. 2009;11(3):227–234.19302282
   PubMed Web of Science ®Google Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 2006;43 Suppl 2:S49–S56. doi:10.1086/50447716894515
   PubMed Web of Science ®Google Scholar
• van Duin D, van Delden C. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):31–41. doi:10.1111/ajt.12096
   Web of Science ®Google Scholar
• Santoro-Lopes G, de Gouvea EF. Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge. World J Gastroenterol. 2014;20(20):6201–6210. doi:10.3748/wjg.v20.i20.620124876740
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect. 2014;20 Suppl 1:1–55. doi:10.1111/1469-0691.12427
   Web of Science ®Google Scholar
• Allocati N, Masulli M, Alexeyev MF, Di Ilio C. Escherichia coli in Europe: an overview. Int J Environ Res Public Health. 2013;10(12):6235–6254. doi:10.3390/ijerph1012623524287850
   PubMed Web of Science ®Google Scholar
• Tourret J, Willing BP, Dion S, MacPherson J, Denamur E, Finlay BB. Immunosuppressive treatment alters secretion of ileal antimicrobial peptides and gut microbiota, and favors subsequent colonization by uropathogenic Escherichia coli. Transplantation. 2017;101(1):74–82. doi:10.1097/TP.000000000000149227681266
   PubMed Web of Science ®Google Scholar
• Aberg F, Makisalo H, Hockerstedt K, Isoniemi H. Infectious complications more than 1 year after liver transplantation: a 3-decade nationwide experience. Am J Transplant. 2011;11(2):287–295. doi:10.1111/ajt.2011.11.issue-221219571
   PubMed Web of Science ®Google Scholar
• Tai Q, He XS, Hu AB, et al. [A 17-year study of bloodstream Escherichia coli infection after liver transplantation: resistance rate, risk factor and mortality]. Zhonghua Yi Xue Za Zhi. 2011;91(42):2977–2980.22333023
   PubMedGoogle Scholar
• Bert F, Larroque B, Paugam-Burtz C, et al. Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transplant. 2010;16(3):393–401. doi:10.1002/lt.21991
   PubMed Web of Science ®Google Scholar
• Janny S, Bert F, Dondero F, et al. Fatal Escherichia coli skin and soft tissue infections in liver transplant recipients: report of three cases. Transplant Infect Dis. 2013;15(2):E49–E53. doi:10.1111/tid.2013.15.issue-2
   Web of Science ®Google Scholar
• Paterson DL, Gruttadauria S, Lauro A, Scott V, Marino IR. Spontaneous gram-negative cellulitis in a liver transplant recipient. Infection. 2001;29(6):345–347. doi:10.1007/s15010-001-1112-z11787838
   PubMed Web of Science ®Google Scholar
• Vila J, Saez-Lopez E, Johnson JR, et al. Escherichia coli: an old friend with new tidings. FEMS Microbiol Rev. 2016;40(4):437–463. doi:10.1093/femsre/fuw00528201713
   PubMed Web of Science ®Google Scholar
• Lee KH, Han SH, Yong D, et al. Acquisition of carbapenemase-producing enterobacteriaceae in solid organ transplantation recipients. Transplant Proc. 2018;50(10):3748–3755. doi:10.1016/j.transproceed.2018.01.05830577266
   PubMed Web of Science ®Google Scholar
• Hauck CG, Chong PP, Miller MB, et al. Increasing rates of fluoroquinolone resistance in Escherichia coli isolated from the blood and urine of patients with hematologic malignancies and stem cell transplant recipients. Pathog Immun. 2016;1(2):234–242. doi:10.20411/pai.v1i2.11528004038
   PubMedGoogle Scholar
• Macesic N, Khan S, Giddins MJ, et al. Escherichia coli harboring mcr-1 in a cluster of liver transplant recipients: detection through active surveillance and whole-genome sequencing. Antimicrob Agents Chemother. 2019;63(6). doi:10.1128/AAC.02680-18
   Web of Science ®Google Scholar
• Pouch SM, Patel G. Multidrug-resistant Gram-negative bacterial infections in solid organ transplant recipients-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;e13594.31102483
   PubMed Web of Science ®Google Scholar